A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

City of Hope Medical Center, Duarte, California, United States

Stanford Cancer Institute, Palo Alto, California, United States

University of Miami Health System, Miami, Florida, United States

The University of Kansas Cancer Center, Westwood, Kansas, United States

Johns Hopkins Hospital, Baltimore, Maryland, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Washington University School of Medicine, St Louis, Missouri, United States

Icahn School of Medicine At Mount Sinai, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Cleveland Clinic, Cleveland, Ohio, United States

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Md Anderson Cancer Center, Houston, Texas, United States